Pro-Dex, Inc. (NASDAQ:PDEX – Get Free Report) Director Angelita Rebamontan Domingo sold 998 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $47.24, for a total transaction of $47,145.52. Following the completion of the transaction, the director owned 18,779 shares of the company’s stock, valued at approximately $887,119.96. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Pro-Dex Price Performance
Shares of NASDAQ:PDEX opened at $56.54 on Thursday. The firm has a market cap of $180.36 million, a PE ratio of 15.62 and a beta of 0.01. The firm’s fifty day moving average is $62.14 and its 200-day moving average is $51.06. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.14 and a current ratio of 3.67. Pro-Dex, Inc. has a 52 week low of $23.47 and a 52 week high of $68.99.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.58. The company had revenue of $19.95 million for the quarter, compared to analysts’ expectations of $17.90 million. Pro-Dex had a net margin of 16.08% and a return on equity of 22.78%. Sell-side analysts predict that Pro-Dex, Inc. will post 3.16 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several brokerages have recently weighed in on PDEX. Weiss Ratings raised Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Ascendiant Capital Markets lifted their target price on shares of Pro-Dex from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Zacks Research upgraded shares of Pro-Dex to a “hold” rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.00.
Get Our Latest Stock Report on PDEX
Pro-Dex Company Profile
Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.
Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.
Featured Articles
- Five stocks we like better than Pro-Dex
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
